Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 3 March 2000:
Vol. 287. no. 5458, pp. 1664 - 1666
DOI: 10.1126/science.287.5458.1664
Prev | Table of Contents

Reports

Epitopes Involved in Antibody-Mediated Protection from Ebola Virus

Julie A. Wilson, Michael Hevey, Russell Bakken, Shawn Guest, Mike Bray, Alan L. Schmaljohn, Mary Kate Hart *

To determine the ability of antibodies to provide protection from Ebola viruses, monoclonal antibodies (mAbs) to the Ebola glycoprotein were generated and evaluated for efficacy. We identified several protective mAbs directed toward five unique epitopes on Ebola glycoprotein. One of the epitopes is conserved among all Ebola viruses that are known to be pathogenic for humans. Some protective mAbs were also effective therapeutically when administered to mice 2 days after exposure to lethal Ebola virus. The identification of protective mAbs has important implications for developing vaccines and therapies for Ebola virus.

Virology Division, U.S. Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Fort Detrick, Frederick, MD 21702-5011, USA.
*   To whom correspondence should be addressed. E-mail: marykate.hart{at}amedd.army.mil

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Cellular and Humoral Immune Responses to Alphavirus Replicon Vaccines Expressing Cytomegalovirus pp65, IE1, and gB Proteins.
E. A. Reap, S. A. Dryga, J. Morris, B. Rivers, P. K. Norberg, R. A. Olmsted, and J. D. Chulay (2007)
Clin. Vaccine Immunol. 14, 748-755
   Abstract »    Full Text »    PDF »
Influences of Glycosylation on Antigenicity, Immunogenicity, and Protective Efficacy of Ebola Virus GP DNA Vaccines.
W. Dowling, E. Thompson, C. Badger, J. L. Mellquist, A. R. Garrison, J. M. Smith, J. Paragas, R. J. Hogan, and C. Schmaljohn (2007)
J. Virol. 81, 1821-1837
   Abstract »    Full Text »    PDF »
Lysis of Human Immunodeficiency Virus Type 1 by a Specific Secreted Human Phospholipase A2.
J.-O. Kim, B. K. Chakrabarti, A. Guha-Niyogi, M. K. Louder, J. R. Mascola, L. Ganesh, and G. J. Nabel (2007)
J. Virol. 81, 1444-1450
   Abstract »    Full Text »    PDF »
Distinct Contributions of Vaccine-Induced Immunoglobulin G1 (IgG1) and IgG2a Antibodies to Protective Immunity against Influenza..
V. C. Huber, R. M. McKeon, M. N. Brackin, L. A. Miller, R. Keating, S. A. Brown, N. Makarova, D. R. Perez, G. H. MacDonald, and J. A. McCullers (2006)
Clin. Vaccine Immunol. 13, 981-990
   Abstract »    Full Text »    PDF »
Development of a cAdVax-Based Bivalent Ebola Virus Vaccine That Induces Immune Responses against both the Sudan and Zaire Species of Ebola Virus.
D. Wang, N. U. Raja, C. M. Trubey, L. Y. Juompan, M. Luo, J. Woraratanadharm, S. B. Deitz, H. Yu, B. M. Swain, K. M. Moore, et al. (2006)
J. Virol. 80, 2738-2746
   Abstract »    Full Text »    PDF »
Protective Cytotoxic T-Cell Responses Induced by Venezuelan Equine Encephalitis Virus Replicons Expressing Ebola Virus Proteins.
G. G. Olinger, M. A. Bailey, J. M. Dye, R. Bakken, A. Kuehne, J. Kondig, J. Wilson, R. J. Hogan, and M. K. Hart (2005)
J. Virol. 79, 14189-14196
   Abstract »    Full Text »    PDF »
Mannose-binding lectin binds to Ebola and Marburg envelope glycoproteins, resulting in blocking of virus interaction with DC-SIGN and complement-mediated virus neutralization.
X. Ji, G. G. Olinger, S. Aris, Y. Chen, H. Gewurz, and G. T. Spear (2005)
J. Gen. Virol. 86, 2535-2542
   Abstract »    Full Text »    PDF »
Induction of Humoral and CD8+ T Cell Responses Are Required for Protection against Lethal Ebola Virus Infection.
K. L. Warfield, G. Olinger, E. M. Deal, D. L. Swenson, M. Bailey, D. L. Negley, M. K. Hart, and S. Bavari (2005)
J. Immunol. 175, 1184-1191
   Abstract »    Full Text »    PDF »
Induction of Long-Term Protective Antiviral Endogenous Immune Response by Short Neutralizing Monoclonal Antibody Treatment.
L. Gros, H. Dreja, A. L. Fiser, M. Plays, M. Pelegrin, and M. Piechaczyk (2005)
J. Virol. 79, 6272-6280
   Abstract »    Full Text »    PDF »
Comprehensive Analysis of Ebola Virus GP1 in Viral Entry.
B. Manicassamy, J. Wang, H. Jiang, and L. Rong (2005)
J. Virol. 79, 4793-4805
   Abstract »    Full Text »    PDF »
Receptor-Binding Domain of Severe Acute Respiratory Syndrome Coronavirus Spike Protein Contains Multiple Conformation-Dependent Epitopes that Induce Highly Potent Neutralizing Antibodies.
Y. He, H. Lu, P. Siddiqui, Y. Zhou, and S. Jiang (2005)
J. Immunol. 174, 4908-4915
   Abstract »    Full Text »    PDF »
Studies of Ebola Virus Glycoprotein-Mediated Entry and Fusion by Using Pseudotyped Human Immunodeficiency Virus Type 1 Virions: Involvement of Cytoskeletal Proteins and Enhancement by Tumor Necrosis Factor Alpha.
A. Yonezawa, M. Cavrois, and W. C. Greene (2005)
J. Virol. 79, 918-926
   Abstract »    Full Text »    PDF »
Role of Natural Killer Cells in Innate Protection against Lethal Ebola Virus Infection.
K. L. Warfield, J. G. Perkins, D. L. Swenson, E. M. Deal, C. M. Bosio, M. J. Aman, W. M. Yokoyama, H. A. Young, and S. Bavari (2004)
J. Exp. Med. 200, 169-179
   Abstract »    Full Text »    PDF »
Persistent Infection with Ebola Virus under Conditions of Partial Immunity.
M. Gupta, S. Mahanty, P. Greer, J. S. Towner, W.-J. Shieh, S. R. Zaki, R. Ahmed, and P. E. Rollin (2004)
J. Virol. 78, 958-967
   Abstract »    Full Text »    PDF »
Ebola virus-like particles protect from lethal Ebola virus infection.
K. L. Warfield, C. M. Bosio, B. C. Welcher, E. M. Deal, M. Mohamadzadeh, A. Schmaljohn, M. J. Aman, and S. Bavari (2003)
PNAS 100, 15889-15894
   Abstract »    Full Text »    PDF »
Monoclonal Antibody 667 Recognizes the Variable Region A Motif of the Ecotropic Retrovirus CasBrE Envelope Glycoprotein and Inhibits Env Binding to the Viral Receptor.
H. Dreja, L. Gros, S. Villard, E. Bachrach, A. Oates, C. Granier, T. Chardes, J.-C. Mani, M. Piechaczyk, and M. Pelegrin (2003)
J. Virol. 77, 10984-10993
   Abstract »    Full Text »    PDF »
Ebola Virus Pathogenesis: Implications for Vaccines and Therapies.
N. Sullivan, Z.-Y. Yang, and G. J. Nabel (2003)
J. Virol. 77, 9733-9737
   Full Text »    PDF »
Intranasal Vaccination Using Interleukin-12 and Cholera Toxin Subunit B as Adjuvants To Enhance Mucosal and Systemic Immunity to Human Immunodeficiency Virus Type 1 Glycoproteins.
D. I. Albu, A. Jones-Trower, A. M. Woron, K. Stellrecht, C. C. Broder, and D. W. Metzger (2003)
J. Virol. 77, 5589-5597
   Abstract »    Full Text »    PDF »
Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology.
F. Bard, R. Barbour, C. Cannon, R. Carretto, M. Fox, D. Games, T. Guido, K. Hoenow, K. Hu, K. Johnson-Wood, et al. (2003)
PNAS 100, 2023-2028
   Abstract »    Full Text »    PDF »
Analysis of Linear B-Cell Epitopes of the Nucleoprotein of Ebola Virus That Distinguish Ebola Virus Subtypes.
M. Niikura, T. Ikegami, M. Saijo, T. Kurata, I. Kurane, and S. Morikawa (2003)
Clin. Vaccine Immunol. 10, 83-87
   Abstract »    Full Text »    PDF »
Identification of Protective Epitopes on Ebola Virus Glycoprotein at the Single Amino Acid Level by Using Recombinant Vesicular Stomatitis Viruses.
A. Takada, H. Feldmann, U. Stroeher, M. Bray, S. Watanabe, H. Ito, M. McGregor, and Y. Kawaoka (2002)
J. Virol. 77, 1069-1074
   Abstract »    Full Text »    PDF »
Covalent Modifications of the Ebola Virus Glycoprotein.
S. A. Jeffers, D. A. Sanders, and A. Sanchez (2002)
J. Virol. 76, 12463-12472
   Abstract »    Full Text »    PDF »
Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody.
A. Nowakowski, C. Wang, D. B. Powers, P. Amersdorfer, T. J. Smith, V. A. Montgomery, R. Sheridan, R. Blake, L. A. Smith, and J. D. Marks (2002)
PNAS 99, 11346-11350
   Abstract »    Full Text »    PDF »
Induction of Immune Responses in Mice and Monkeys to Ebola Virus after Immunization with Liposome-Encapsulated Irradiated Ebola Virus: Protection in Mice Requires CD4+ T Cells.
M. Rao, M. Bray, C. R. Alving, P. Jahrling, and G. R. Matyas (2002)
J. Virol. 76, 9176-9185
   Abstract »    Full Text »    PDF »
Antibodies Highly Effective in SCID Mice During Infection by the Intracellular Bacterium Ehrlichia chaffeensis Are of Picomolar Affinity and Exhibit Preferential Epitope and Isotype Utilization.
J. S.-y. Li, F. Chu, A. Reilly, and G. M. Winslow (2002)
J. Immunol. 169, 1419-1425
   Abstract »    Full Text »    PDF »
Pre- and Postexposure Prophylaxis of Ebola Virus Infection in an Animal Model by Passive Transfer of a Neutralizing Human Antibody.
P. W. H. I. Parren, T. W. Geisbert, T. Maruyama, P. B. Jahrling, and D. R. Burton (2002)
J. Virol. 76, 6408-6412
   Abstract »    Full Text »    PDF »
Lipid Raft Microdomains: A Gateway for Compartmentalized Trafficking of Ebola and Marburg Viruses.
S. Bavari, C. M. Bosio, E. Wiegand, G. Ruthel, A. B. Will, T. W. Geisbert, M. Hevey, C. Schmaljohn, A. Schmaljohn, and M. J. Aman (2002)
J. Exp. Med. 195, 593-602
   Abstract »    Full Text »    PDF »
Reverse Genetics Demonstrates that Proteolytic Processing of the Ebola Virus Glycoprotein Is Not Essential for Replication in Cell Culture.
G. Neumann, H. Feldmann, S. Watanabe, I. Lukashevich, and Y. Kawaoka (2002)
J. Virol. 76, 406-410
   Abstract »    Full Text »    PDF »
Biosynthesis and role of filoviral glycoproteins.
H. Feldmann, V. E. Volchkov, V. A. Volchkova, U. Stroher, and H.-D. Klenk (2001)
J. Gen. Virol. 82, 2839-2848
   Full Text »    PDF »
Fc Receptor-Mediated Phagocytosis Makes a Significant Contribution to Clearance of Influenza Virus Infections.
V. C. Huber, J. M. Lynch, D. J. Bucher, J. Le, and D. W. Metzger (2001)
J. Immunol. 166, 7381-7388
   Abstract »    Full Text »    PDF »
The role of the Type I interferon response in the resistance of mice to filovirus infection.
M. Bray (2001)
J. Gen. Virol. 82, 1365-1373
   Abstract »    Full Text »
Ebola Virus VP40-Induced Particle Formation and Association with the Lipid Bilayer.
L. D. Jasenosky, G. Neumann, I. Lukashevich, and Y. Kawaoka (2001)
J. Virol. 75, 5205-5214
   Abstract »    Full Text »
Passive Transfer of Antibodies Protects Immunocompetent and Immunodeficient Mice against Lethal Ebola Virus Infection without Complete Inhibition of Viral Replication.
M. Gupta, S. Mahanty, M. Bray, R. Ahmed, and P. E. Rollin (2001)
J. Virol. 75, 4649-4654
   Abstract »    Full Text »
Protection from Ebola Virus Mediated by Cytotoxic T Lymphocytes Specific for the Viral Nucleoprotein.
J. A. Wilson and M. K. Hart (2001)
J. Virol. 75, 2660-2664
   Abstract »    Full Text »
Infectivity-Enhancing Antibodies to Ebola Virus Glycoprotein.
A. Takada, S. Watanabe, K. Okazaki, H. Kida, and Y. Kawaoka (2001)
J. Virol. 75, 2324-2330
   Abstract »    Full Text »


ADVERTISEMENT
Click Me!

ADVERTISEMENT
Click Me!

To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)